See other companies on Welcome to the Jungle
Click Therapeutics
Developing software as prescription treatments
- 101-200 employees
- Healthcare
- B2C
- B2B
- SaaS
- Biotechnology
- Chinatown, New York, NY
Jump to section
Company mission
To deliver safe and effective digital treatments to patients in need.
18% employee growth in 12 months
Our take
Prescription medical treatments have historically been comprised only of pharmaceutical drugs and therapies, but digital therapeutics present an effective and low-cost alternative. With treatment provided through a clinically trialled app, these solutions have found success in tackling major medical issues such as type 2 diabetes, depression and smoking.
Click Therapeutics is one company working in this field, providing prescription software as a treatment for patients with unmet and high-burden needs such as chronic pain, major depressive disorder and migraines. There are many other companies working in this area, but its a rapidly growing market so there's plenty of room for competition.
Click Therapeutics is well-funded, leveraging capital to accelerate the development of its products and further improve the performance of its platform. And, as the efficacy of digital therapeutics becomes more widely-known, it is in a strong position to grow. FDA approval for its Rejoyn app, which helps treat major depressive disorder, is also a great step in the right direction.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Annual performance-based cash bonus
- Choice of Mac, Windows, or Linux equipment
- Life insurance and disability benefits
- Monthly catered lunches
- Sponsored company events
- Generous paid parental leave
- Unlimited PTO
- Stock options
- Flexible Spending Accounts
- 401(k) matching
- Comprehensive medical benefits through Aetna
- Open vacation policy
- Commuter subsidies
- Free, unlimited office snacks and beverages
Company values
- Patients first
- Act with integrity
- Expect excellence
- No jerks
- Own it
- Make work fun
Funding (last 2 of 9 rounds)
Oct 2021
$52m
SERIES B
Oct 2018
$19m
EARLY VC
Total funding: $96.6m
Leadership
David Benshoof Klein
(Founder & CEO)Experience as Managing Director of Opus Point Partners from 2007 to 2012. Senior Consultant of Pfizer from 2012 to 2014.